Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-cash Items: 2012-2025

Historic Non-cash Items for Gyre Therapeutics (GYRE) over the last 10 years, with Sep 2025 value amounting to $15.8 million.

  • Gyre Therapeutics' Non-cash Items fell 11.67% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 11.67%. This contributed to the annual value of $190.4 million for FY2024, which is 57.14% down from last year.
  • Per Gyre Therapeutics' latest filing, its Non-cash Items stood at $15.8 million for Q3 2025, which was up 0.91% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Non-cash Items registered a high of $444.2 million during Q4 2023, and its lowest value of $1.2 million during Q1 2021.
  • Moreover, its 3-year median value for Non-cash Items was $16.2 million (2025), whereas its average is $69.0 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 3,406.73% in 2023, then tumbled by 57.14% in 2024.
  • Gyre Therapeutics' Non-cash Items (Quarterly) stood at $1.5 million in 2021, then spiked by 737.19% to $12.7 million in 2022, then surged by 3,406.73% to $444.2 million in 2023, then crashed by 57.14% to $190.4 million in 2024, then declined by 11.67% to $15.8 million in 2025.
  • Its Non-cash Items stands at $15.8 million for Q3 2025, versus $15.6 million for Q2 2025 and $16.2 million for Q1 2025.